378 related articles for article (PubMed ID: 19762091)
1. Is resistance useless? Multidrug resistance and collateral sensitivity.
Hall MD; Handley MD; Gottesman MM
Trends Pharmacol Sci; 2009 Oct; 30(10):546-56. PubMed ID: 19762091
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
3. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
[TBL] [Abstract][Full Text] [Related]
4. The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells.
Bakadlag R; Limniatis G; Georges G; Georges E
BMC Cancer; 2023 Jan; 23(1):24. PubMed ID: 36609245
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
6. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
8. SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells.
Xu SW; Law BYK; Qu SLQ; Hamdoun S; Chen J; Zhang W; Guo JR; Wu AG; Mok SWF; Zhang DW; Xia C; Sugimoto Y; Efferth T; Liu L; Wong VKW
Pharmacol Res; 2020 Mar; 153():104660. PubMed ID: 31982489
[TBL] [Abstract][Full Text] [Related]
9. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review.
Dong J; Yuan L; Hu C; Cheng X; Qin JJ
Pharmacol Ther; 2023 Sep; 249():108488. PubMed ID: 37442207
[TBL] [Abstract][Full Text] [Related]
10. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
11. The role of P-glycoprotein in drug resistance in multiple myeloma.
Abraham J; Salama NN; Azab AK
Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
[TBL] [Abstract][Full Text] [Related]
12. Collateral sensitivity as a strategy against cancer multidrug resistance.
Pluchino KM; Hall MD; Goldsborough AS; Callaghan R; Gottesman MM
Drug Resist Updat; 2012; 15(1-2):98-105. PubMed ID: 22483810
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C
J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606
[TBL] [Abstract][Full Text] [Related]
14. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
Waghray D; Zhang Q
J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
[TBL] [Abstract][Full Text] [Related]
15. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
Zhou SF
Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
17. The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
Zhang H; Patel A; Wang YJ; Zhang YK; Kathawala RJ; Qiu LH; Patel BA; Huang LH; Shukla S; Yang DH; Ambudkar SV; Fu LW; Chen ZS
Mol Cancer Ther; 2017 Jun; 16(6):1021-1030. PubMed ID: 28265007
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.
Hui RC; Francis RE; Guest SK; Costa JR; Gomes AR; Myatt SS; Brosens JJ; Lam EW
Mol Cancer Ther; 2008 Mar; 7(3):670-8. PubMed ID: 18347152
[TBL] [Abstract][Full Text] [Related]
19. Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-glycoprotein.
Teng YN; Wang CCN; Liao WC; Lan YH; Hung CC
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936160
[No Abstract] [Full Text] [Related]
20. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
